← All trials
NCT03815318
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 21, 2019
- Primary completion
- Aug 21, 2019
- Completion date
- Oct 21, 2019
- First posted
- —
- Last posted
- —
- Enrollment
- 68
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Sinocelltech Ltd.Lead sponsor
- ParexelCollaborator
- Chinese Academy of Medical SciencesCollaborator
- Q2 solutionsCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.